Tolerability of Bimatoprost 0.01% vs Latanoprost Eye Drops
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02138461|
Recruitment Status : Completed
First Posted : May 14, 2014
Results First Posted : September 25, 2014
Last Update Posted : September 25, 2014
|Condition or disease|
|Study Type :||Observational|
|Actual Enrollment :||211 participants|
|Official Title:||Subjective Patient Assessment Comparing Overall Tolerability and Satisfaction of a Prostaglandin Analogue Including Either Bimatoprost 0.01% or Latanoprost.|
|Study Start Date :||October 2013|
|Actual Primary Completion Date :||September 2014|
|Actual Study Completion Date :||September 2014|
These patients take bimatoprost topically for glaucoma.
These patients take latanoprost topically for glaucoma.
- Tolerability of Medications as Measured by the COMTOL Validated Instrument [ Time Frame: at the time of enrollment in the clinic, patients will immediately complete the questionnaire and exit the study ]Patients who are already taking the medications of interest will be enrolled from a general ophthalmology practice. Immediately after consenting to participate, they will complete a validated survey instrument called the Comparison of Ophthalmic Medication for Primary Outcome Measure Tolerability (COMTOL) questionnaire (Ophthalmology 1997; : 104:334-342). Because this study will not be a crossover trial design, and patients will only continue taking the medications they were prescribed in the course of their glaucoma therapy, the modified version will eliminate questions in the COMTOL related to subjective comparison of two medications and instead focus on tolerability of the single medication being taken by test subjects.
Biospecimen Retention: None Retained
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02138461
|United States, California|
|Harvard Eye Associates|
|Laguna Hills, California, United States, 92653|
|Principal Investigator:||John A. Hovanesian, MD||UCLA Jules Stein Eye Institute|
|Principal Investigator:||Savak Teymoorian, MD||Harvard Eye Associates|